These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24164503)

  • 1. Recent progress in the treatment of cardiovascular disease using olmesartan.
    Miura S; Saku K
    Clin Exp Hypertens; 2014; 36(7):441-6. PubMed ID: 24164503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP
    Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.
    Omboni S; Volpe M
    Cardiovasc Ther; 2018 Dec; 36(6):e12471. PubMed ID: 30358114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
    J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
    de la Sierra A; Volpe M
    J Hypertens; 2013 Mar; 31 Suppl 1():S13-7. PubMed ID: 23389083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difficult-to-control hypertension: effects of olmesartan-based combination therapies.
    de la Sierra A
    J Hypertens; 2013 Mar; 31 Suppl 1():S1-2. PubMed ID: 23389082
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y
    Clin Sci (Lond); 2006 Mar; 110(3):379-86. PubMed ID: 16336207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update.
    Chrysant SG; Dimas B; Shiraz M
    J Hum Hypertens; 2007 Sep; 21(9):699-708. PubMed ID: 17554345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders.
    Fyhrquist F; Metsärinne K; Tikkanen I
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S19-24. PubMed ID: 8583476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers - advantages of the new sartans.
    Sabbah ZA; Mansoor A; Kaul U
    J Assoc Physicians India; 2013 Jul; 61(7):464-70. PubMed ID: 24772750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of olmesartan on tissue expression balance between angiotensin II receptor and its inhibitory binding molecule.
    Shigenaga A; Tamura K; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Ozawa M; Mogi M; Matsuda M; Uchino K; Kimura K; Horiuchi M; Umemura S
    Hypertension; 2008 Oct; 52(4):672-8. PubMed ID: 18725581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
    Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
    Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2010 Jun; 11(9):1549-58. PubMed ID: 20446761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
    Scholze J; Schaefer A; Kreutz R
    Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
    Ferrario C
    Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
    Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
    Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.